For the past 48 years Prof. Chabner has devoted himself to a career in cancer research and drug development. He directed the Drug Development Program and the clinical trials efforts of the National Cancer Institute, as Director of the Division of Cancer Treatment, for 14 years (1981-1995), and have designed, participated in, and reported clinical and laboratory studies of new agents, including maytansine, folate analogues, paclitaxel, fludarabine, and yondelis. He moved to Harvard Medical School and the Massachusetts General Hospital many years ago, where he was Chief of the Division of Hematology/Oncology from 1995-2006 and Clinical Director of the MGH Cancer Center from 1995-2010.